1. ALLA AKTIER
  2. NYHETER
  3. SENZAGEN

SenzaGen

Nyheter SenzaGen Nyheter alla bolag

SenzaGen strengthens its market presence with expanded distribution channels

SenzaGen has signed agreements with CRO companies GV Research Platform (GVRP) in India and Oroxcell in France for the distribution of the company's non-animal test portfolio, GARD® for chemical risk assessment. These strategic partnerships will enable the broadened distribution of GARD® to key markets driven by regulatory and industrial demand for alternative testing methods.

India is a potentially important and large market where SenzaGen has already noticed increased interest in GARD® and has successfully secured orders from Indian customers. By collaborating with GVRP, a prominent CRO and distribution company in India, SenzaGen now gains access to a robust network and expertise in the country’s thriving Life Science sector.

Similarly, SenzaGen’s partnership with Oroxcell, an well-established CRO in France, strengthens the company’s presence in one of its key geographic markets. France, known for its world-leading companies in cosmetics and pharmaceuticals, has long upheld a ban on animal testing for cosmetics as a member of the EU. With Oroxcell’s strong focus on innovative, animal-free methods, SenzaGen will benefit from their broad network of contacts and specialist knowledge.

”Expanding SenzaGen’s distribution channels is a crucial part of our scaling up as a commercial company. With the addition of two new quality distributors in important markets where we see an increasing demand for GARD®, we are taking important steps on our growth journey,” says Peter Nählstedt, President and CEO of SenzaGen.

Both distributors will actively promote GARD® in their test portfolio, with a focus on biotech, pharma, chemical, and cosmetic companies seeking advanced testing solutions. All tests will be conducted at SenzaGen’s GLP certified laboratory in Lund, Sweden.

About GV Research Platform (GVRP)
Headquartered in Hyderabad, India, GV Research Platform (GVRP) is a pioneering Contract Research Organization focused on providing end-to-end solutions across the drug discovery continuum. Since its establishment in 2020, GVRP has made significant strides towards its vision of enabling efficient and affordable innovation through differentiated and customized R&D solutions. For more information, please visit www.gvrp.in

About Oroxcell
Oroxcell was founded in 2004. Specialized in efficacy, ADME and toxicity studies for pharmaceutical, cosmetics, nutrition and chemicals products, Oroxcell is a leading CRO company developing alternative methods to animal use. Once validated, these tests are provided as R&D services to its customers. For more information, please visit www.oroxcell.com

Contacts

Peter Nählstedt, President and CEO, SenzaGen AB
Email: peter.nahlstedt@senzagen.com | Mobile: +46 700 23 44 31

Tina Dackemark Lawesson, VP Marketing & Communications
Email: tina.lawesson@senzagen.com | Mobile: +46 708 20 29 44

About us

SenzaGen aims to be a leader in in vitro science and testing, driving the transition from animal testing to methods better suited to reflect human biology. The Company provides high-performance, non-animal test methods and innovation and consulting services based on state-of-the-art technology. Non-animal methods are more effective, more accurate and less expensive than traditional animal-based methods while also helping to reduce the number of laboratory animals. The Company has a growth strategy centered around continued commercialization of its proprietary GARD® and VitroScreen ORA® test platforms, expansion of its test portfolio and evaluation of acquisition opportunities of profitable and growing companies with complementary offerings. SenzaGen has its headquarters and GLP-certified laboratory in Lund, Sweden and subsidiaries in the US and Italy. For more information, please visit: www.senzagen.com.

SenzaGen is listed on Nasdaq Stockholm First North (ticker: SENZA). FNCA Sweden AB is the company’s Certified Adviser. 

Attachments

SenzaGen strengthens its market presence with expanded distribution channels

Datum 2023-07-07, kl 08:30
Källa MFN
Bifogade filer
SenzaGen strengthens its market presence with expanded distribution channels
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 10 000 unika besökare per månad. Vår discord har över 5000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!